--- title: "Sensei appoints Stephen M. Hahn, Saira Ramasastry and Karen Vousden as directors; Christopher W. Gerry, Thomas Ricks and Kristian Humer to resign" type: "News" locale: "en" url: "https://longbridge.com/en/news/283047930.md" description: "Sensei Biotherapeutics will see the conditional resignations of Christopher W. Gerry, Thomas Ricks, and Kristian Humer, while appointing Stephen M. Hahn, Saira Ramasastry, and Karen Vousden as directors, pending stockholder approval at the June 10, 2026 annual meeting. The changes are contingent on the approval of Conversion and Charter Amendment Proposals. Hahn is anticipated to become CEO, and Ramasastry will likely serve as CFO following the meeting." datetime: "2026-04-16T20:03:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283047930.md) - [en](https://longbridge.com/en/news/283047930.md) - [zh-HK](https://longbridge.com/zh-HK/news/283047930.md) --- # Sensei appoints Stephen M. Hahn, Saira Ramasastry and Karen Vousden as directors; Christopher W. Gerry, Thomas Ricks and Kristian Humer to resign **Sensei will see Christopher W. Gerry, Thomas Ricks and Kristian Humer tender conditional resignations and conditionally appoint Stephen M. Hahn, Saira Ramasastry and Karen Vousden to the board, contingent on stockholder approval of two proposals at the June 10, 2026 annual meeting.** **Individual** Christopher W. Gerry Thomas Ricks Kristian Humer Stephen M. Hahn Saira Ramasastry Karen Vousden Anand Parikh Brian Stephenson, Ph.D. Josiah Craver **Role** President, General Counsel, Board member Board member Board member Director; expected Class III director; Nominating & Corporate Governance Committee member Director; expected Class III director; Audit Committee & Compensation Committee member Director; expected Class II director; Compensation Committee member and Chair of Nominating & Corporate Governance Committee Chief Operating Officer; Board member Head of Operations and Finance Senior Vice President of Finance **Type of Change** Conditional resignation Conditional resignation Conditional resignation Conditional appointment Conditional appointment Conditional appointment Anticipated appointment as Chief Executive Officer Anticipated appointment as Chief Financial Officer Will cease to be principal financial officer **Effective Date** Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Two business days after conclusion of June 10, 2026 Annual Meeting (Effective Time), contingent on stockholder approvals Upon approval of Required Company Stockholder Proposals (Effective Time) Upon approval of Required Company Stockholder Proposals (Effective Time) Upon approval of Required Company Stockholder Proposals (Effective Time) **Reason** Resignation contingent on stockholder approval of Conversion and Charter Amendment Proposals; not due to disagreement Resignation contingent on stockholder approval of Conversion and Charter Amendment Proposals; not due to disagreement Resignation contingent on stockholder approval of Conversion and Charter Amendment Proposals; not due to disagreement Appointment contingent on stockholder approval of Conversion and Charter Amendment Proposals Appointment contingent on stockholder approval of Conversion and Charter Amendment Proposals Appointment contingent on stockholder approval of Conversion and Charter Amendment Proposals Board anticipates appointing him CEO if Required Company Stockholder Proposals are approved Board anticipates appointing him CFO if Required Company Stockholder Proposals are approved Will cease serving as principal financial officer upon appointment of new CFO **Replacement Info** Expected to be succeeded on Board by incoming directors upon Effective Time Expected to be succeeded on Board by incoming directors upon Effective Time Expected to be succeeded on Board by incoming directors upon Effective Time N/A N/A N/A Will succeed Christopher W. Gerry as principal executive officer Will succeed Josiah Craver as principal financial officer Expected to continue as Senior VP Finance and principal accounting officer **Background Details** Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Currently Chief Operating Officer and Board member Currently Head of Operations and Finance Currently Senior Vice President of Finance **Board/Committee Role Changes** Will cease to be President; expected to remain General Counsel Not disclosed Not disclosed Expected Nominating & Corporate Governance Committee member Expected Audit & Compensation Committee member Expected Compensation Committee member and Chair of Nominating & Corporate Governance Committee Will remain Board member Will become principal financial officer Will continue as principal accounting officer Original SEC Filing: Sensei Biotherapeutics, Inc. \[ SNSE \] - 8-K - Apr. 16, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [SNSE.US](https://longbridge.com/en/quote/SNSE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md) - [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md) - [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)